Halozyme Therapeutics, Inc. (NASDAQ:HALO) to Post FY2022 Earnings of $1.99 Per Share, Zacks Research Forecasts

Halozyme Therapeutics, Inc. (NASDAQ:HALOGet Rating) – Equities researchers at Zacks Research lowered their FY2022 earnings per share estimates for Halozyme Therapeutics in a research report issued on Monday, September 19th. Zacks Research analyst I. Bandyopadhyay now anticipates that the biopharmaceutical company will earn $1.99 per share for the year, down from their previous forecast of $2.01. The consensus estimate for Halozyme Therapeutics’ current full-year earnings is $1.93 per share. Zacks Research also issued estimates for Halozyme Therapeutics’ Q4 2022 earnings at $0.53 EPS, Q1 2023 earnings at $0.65 EPS, Q2 2023 earnings at $0.68 EPS, Q3 2023 earnings at $0.74 EPS, Q4 2023 earnings at $0.72 EPS, FY2023 earnings at $2.79 EPS, Q1 2024 earnings at $0.87 EPS, Q2 2024 earnings at $1.00 EPS and FY2024 earnings at $3.67 EPS.

Halozyme Therapeutics (NASDAQ:HALOGet Rating) last announced its earnings results on Tuesday, August 9th. The biopharmaceutical company reported $0.53 EPS for the quarter, topping the consensus estimate of $0.47 by $0.06. The company had revenue of $152.37 million for the quarter, compared to analysts’ expectations of $156.00 million. Halozyme Therapeutics had a return on equity of 101.73% and a net margin of 75.11%. The business’s revenue for the quarter was up 11.7% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.63 earnings per share.

HALO has been the topic of several other research reports. The Goldman Sachs Group raised their price target on Halozyme Therapeutics from $48.00 to $60.00 and gave the company a “buy” rating in a report on Thursday, May 26th. Morgan Stanley began coverage on Halozyme Therapeutics in a report on Friday, September 9th. They issued an “overweight” rating and a $50.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, Halozyme Therapeutics has an average rating of “Moderate Buy” and an average price target of $52.00.

Halozyme Therapeutics Price Performance

Halozyme Therapeutics stock opened at $40.28 on Wednesday. The business’s 50-day simple moving average is $44.31 and its 200 day simple moving average is $43.05. The stock has a market cap of $5.55 billion, a price-to-earnings ratio of 15.92, a P/E/G ratio of 0.70 and a beta of 1.25. Halozyme Therapeutics has a 12-month low of $31.36 and a 12-month high of $52.98. The company has a quick ratio of 2.23, a current ratio of 2.72 and a debt-to-equity ratio of 3.91.

Hedge Funds Weigh In On Halozyme Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in HALO. First Horizon Advisors Inc. boosted its holdings in Halozyme Therapeutics by 188.8% during the second quarter. First Horizon Advisors Inc. now owns 722 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 472 shares during the last quarter. Meeder Asset Management Inc. boosted its holdings in Halozyme Therapeutics by 223.6% during the second quarter. Meeder Asset Management Inc. now owns 741 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 512 shares during the last quarter. Brown Brothers Harriman & Co. bought a new position in Halozyme Therapeutics during the second quarter worth about $35,000. San Luis Wealth Advisors LLC bought a new position in Halozyme Therapeutics during the first quarter worth about $36,000. Finally, Selective Wealth Management Inc. acquired a new stake in shares of Halozyme Therapeutics during the second quarter worth about $44,000. Institutional investors own 91.72% of the company’s stock.

About Halozyme Therapeutics

(Get Rating)

Halozyme Therapeutics, Inc operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

Featured Articles

Earnings History and Estimates for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.